Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-02-10
2008-12-30
Russel, Jeffrey E (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S012200, C514S013800, C514S021800, C514S04400A, C514S078000
Reexamination Certificate
active
07470660
ABSTRACT:
The present invention addresses the treatment of age-related macular degeneration, and treatment of individuals with impaired visual function such as impaired dark adaptation, using regulation of pathogenic mechanisms similar to atherosclerosis. In further specific embodiments, compositions that increase reverse cholesterol transport are utilized as therapeutic targets for age-related macular degeneration and improving impaired dark adaptation. In a specific embodiment, the lipid content of the retinal pigment epithelium, and/or Bruch's membrane is reduced by delivering Apolipoprotein A1, particularly a mimetic peptide.
REFERENCES:
patent: 5080478 (1992-01-01), O'Brien et al.
patent: 5721114 (1998-02-01), Abrahamsen et al.
patent: 5733761 (1998-03-01), Treco et al.
patent: 5780592 (1998-07-01), Mullner et al.
patent: 5824685 (1998-10-01), Campochiaro et al.
patent: 5866551 (1999-02-01), Benoit et al.
patent: 5990081 (1999-11-01), Ageland et al.
patent: 6033885 (2000-03-01), Latta et al.
patent: 6071924 (2000-06-01), Campochiaro et al.
patent: 6075032 (2000-06-01), Campochiaro et al.
patent: 6090921 (2000-07-01), Winge et al.
patent: 6258596 (2001-07-01), Benoit et al.
patent: 6287590 (2001-09-01), Dasseux
patent: 6320074 (2001-11-01), Boehm et al.
patent: 6329341 (2001-12-01), Dasseux et al.
patent: 6367479 (2002-04-01), Williams
patent: 6369098 (2002-04-01), Pershadsingh et al.
patent: 6372753 (2002-04-01), Campochiaro et al.
patent: 6376464 (2002-04-01), Dasseux et al.
patent: 6423830 (2002-07-01), Winge et al.
patent: 6506879 (2003-01-01), Ageland et al.
patent: 6555582 (2003-04-01), Schwartz et al.
patent: 6559284 (2003-05-01), Ageland et al.
patent: 6617134 (2003-09-01), Sirtori et al.
patent: RE38556 (2004-07-01), Benoit et al.
patent: 6844327 (2005-01-01), Dasseux et al.
patent: 7250407 (2007-07-01), Dasseux et al.
patent: 2001/0006656 (2001-07-01), Harlan et al.
patent: 2002/0102581 (2002-08-01), Hageman et al.
patent: 2003/0032078 (2003-02-01), Travis
patent: 2003/0065020 (2003-04-01), Gale et al.
patent: 2003/0114515 (2003-06-01), Kaesemeyer
patent: 2003/0149997 (2003-08-01), Hageman
patent: 2003/0162758 (2003-08-01), Schwartz et al.
patent: 2003/0229062 (2003-12-01), Schwartz et al.
patent: 2004/0266663 (2004-12-01), Schwartz et al.
patent: WO-00/52479 (2000-09-01), None
patent: WO-00/52479 (2000-09-01), None
patent: WO-01/06262 (2001-01-01), None
patent: WO-01/58494 (2001-08-01), None
patent: WO-01/58494 (2001-08-01), None
patent: WO-02/13812 (2002-02-01), None
Blankenhorn, David H., et al. ; Reversal of Atherosis and Sclerosis; Circulation 79(1):1-7, Jan. 1989.
Mullins, Robert F., et al. ; Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atheroclerosis, elastosis, amyloidosis, and dense deposit disease; FASEB J, 14:835-846,2000.
Simonelli, Francesca, et al.; Apolipoprotein E Polymorphisms in Ae-Related Macular Degeneration in an Italian Population; Ophthalmic Res 33:325-328, 2001.
Milam, Ann H., et al. ; Dominant Late-onset Retinal degeneration with Regional Variation of Sub-Retinal Pigment Epithelium Deposits, Retinal Function and Photoreceptor Degeneration; Ophthalmology 107:2256-2266,2000.
Johnson, Lincoln V. et al., Complement Activation and Inflammatory Processes in Drusen Formation and Age Related Macular Degeneration; Exp. Eye Res. 73:887-896, 2001.
Friedman, Ephraim; The Role of the Atherosclerotic Process in the Pathogenesis of Age-relat4ed Macular Degeneration; American Journal of Ophthalmology 130(5):658-663, 2000.
Schmidt, Silke, et al.; Association of the Apolipoprotein E gene with age-related macular degeneration: Possible effect modification by family history, age, and gender; Molecular Vision 6;287-293, 2000.
Klaver, Caroline C.W. et al.; Genetic Association of Apolipoprotein E with Age-Related Macular Degeneration; Am.J. Hum. Genet. 63:200-206, 1998.
Anderson, Don H., et al.:; Local Cellular Sources of Apolipoprotein E in the Human Retina and Retinal Pigmented Epithelium: Implications for the Process of Drusen Formation; Am J. Ophthalmol 131:767-781.2001.
Database NCBI Online, “Homo sapiens preapolipoprotein E (APOE) mRNA, complete cds.”, K00396, (2002).
Database NCBI Online, “Human apolipoprotein E (epsilon-4 allele) gene, complete cds”, M10065, (1994).
Database NCBI Online, “Human apolipoprotein E mRNA, complete cds”, M12529, (1995) .
Database NCBI Online, “Preapolipoprotein E [Homo sapiens]”, AAB59546, (2002).
Database NCBI Online, “Apolipoprotein E”, AAB59397, (1994).
Database NCBI Online, “Apolipoprotein E”, AAB59518, (1995).
Database NCBI Online, “Homo sapiens ATP-binding cassette, sub-family A (ABC1), member 1 (ANCA1), mRNA”, NM—005502, (2008).
Database NCBI Online, “Homo sapiens mRNA for ABCA1, complete cds”, AB055982, (2008).
Database NCBI Online, “ATP-binding cassette, sub-family A member 1 [Homo sapiens]”, NP—005493, (2008).
Database NCBI Online, “ABCA1 [Homo sapiens]”, BAB63210, (2001).
Database NCBI Online, “Homo sapiens scavenger receptor class B, member 1 (SCARB1), transcript variant 1, mRNA”, NM—005505, (2008).
Database NCBI Online, “Sscavenger receptor class B, member 1 isoform 1 [Homo sapiens]”, NP—005496, (2008).
Leeuwen et al. Risk of macular degeneration with station use should be interpreted with caution, British Medical Medical Journal, 323:1308-1308, 2001.
Melnikova I., Raising HDL cholesterol, Nature Reviews Drug Discovery 4, 185-186 (Mar. 2005).
Miller M., Raising an isolated low HDL-C level: Why, how, and when? Cleveland Clinic Journal Of Medicine 70(6) 53-560 (Jun. 2003).
Bailey Kathy
Duncan Keith G.
Ishida Brian Y.
Kane John P.
Schwartz Daniel M.
Fulbright & Jaworski LLP
Russel Jeffrey E
The Regents of the University of California
LandOfFree
Treatment for dark adaptation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment for dark adaptation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment for dark adaptation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4031514